– Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government-regulated industries, closed
Arlington Capital Partners VII (“ACP VII” or the “Fund”) with $6.0 billion in capital commitments.
– The Fund was significantly oversubscribed, reaching its hard cap in less than five months and surpassing its $4.75 billion target.
– ACP VII represents a 57% increase over Arlington Capital Partners VI (closed 2023) and a more than 250% increase from Arlington Capital Partners V (closed 2019).
– The Managing Partners highlighted strong investment opportunities driven by increasing domestic and international national security budgets, revitalization of U.S. manufacturing, and growth in government software and tech-enabled services.
– ACP VII continues Arlington’s 26-year track record of building transformative companies in aerospace and defense, government services and technology, and healthcare.
– Since 1999, Arlington has completed approximately 200 investments in its focus areas.
– In 2024, Arlington invested over $1 billion across 35 investments.
– The Firm has executed multiple successful exits, including the sale of BlueHalo to AV (NASDAQ: AVAV), creating a global defense technology leader.
– Arlington and its portfolio companies operate approximately 10 million square feet of U.S. manufacturing space, contributing significantly to local economies.
– ACP VII’s investor base includes leading U.S. and select allied-country pensions, asset managers, insurers, endowments, foundations, and other institutions.
– Re-up demand from Fund VI investors exceeded 115%, reflecting strong continued support.
– ACP VII will focus on long-term investment themes including manufacturing and supply chain onshoring, mission-critical government software, next-generation defense tech, cybersecurity, commercial aviation, advanced medical devices, life sciences, and healthcare technology.
Arlington Capital Partners VII (“ACP VII” or the “Fund”) with $6.0 billion in capital commitments.
– The Fund was significantly oversubscribed, reaching its hard cap in less than five months and surpassing its $4.75 billion target.
– ACP VII represents a 57% increase over Arlington Capital Partners VI (closed 2023) and a more than 250% increase from Arlington Capital Partners V (closed 2019).
– Arlington’s Managing Partners are Matt Altman, Michael Lustbader, Peter Manos, and David Wodlinger.
– The Managing Partners highlighted strong investment opportunities driven by increasing domestic and international national security budgets, revitalization of U.S. manufacturing, and growth in government software and tech-enabled services.
– ACP VII continues Arlington’s 26-year track record of building transformative companies in aerospace and defense, government services and technology, and healthcare.
– Since 1999, Arlington has completed approximately 200 investments in its focus areas.
– In 2024, Arlington invested over $1 billion across 35 investments.
– The Firm has executed multiple successful exits, including the sale of BlueHalo to AV (NASDAQ: AVAV), creating a global defense technology leader.
– Arlington and its portfolio companies operate approximately 10 million square feet of U.S. manufacturing space, contributing significantly to local economies.
– ACP VII’s investor base includes leading U.S. and select allied-country pensions, asset managers, insurers, endowments, foundations, and other institutions.
– Re-up demand from Fund VI investors exceeded 115%, reflecting strong continued support.
– ACP VII will focus on long-term investment themes including manufacturing and supply chain onshoring, mission-critical government software, next-generation defense tech, cybersecurity, commercial aviation, advanced medical devices, life sciences, and healthcare technology.